121 related articles for article (PubMed ID: 7596261)
1. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study.
Holshouser BA; Komu M; Möller HE; Zijlmans J; Kolem H; Hinshaw DB; Sonninen P; Vermathen P; Heerschap A; Masur H
Magn Reson Med; 1995 May; 33(5):589-94. PubMed ID: 7596261
[TBL] [Abstract][Full Text] [Related]
2. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR
Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574
[TBL] [Abstract][Full Text] [Related]
3. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
[TBL] [Abstract][Full Text] [Related]
4. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Federico F; Simone IL; Lucivero V; Iliceto G; De Mari M; Giannini P; Mezzapesa DM; Tarantino A; Lamberti P
Mov Disord; 1997 Nov; 12(6):903-9. PubMed ID: 9399213
[TBL] [Abstract][Full Text] [Related]
5. Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
Cruz CJ; Aminoff MJ; Meyerhoff DJ; Graham SH; Weiner MW
Magn Reson Imaging; 1997; 15(6):619-24. PubMed ID: 9285801
[TBL] [Abstract][Full Text] [Related]
6. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
Baik HM; Choe BY; Son BC; Jeun SS; Kim MC; Lee KS; Kim BS; Lee JM; Lee HK; Suh TS
Eur J Radiol; 2003 Sep; 47(3):179-87. PubMed ID: 12927660
[TBL] [Abstract][Full Text] [Related]
7. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U
Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082
[TBL] [Abstract][Full Text] [Related]
8. Localized proton NMR spectroscopy in the striatum of patients with idiopathic spasmodic torticollis.
Möller HE; Vollmer-Haase J; Wiedermann D; Schuierer G
Magn Reson Med; 1998 Feb; 39(2):309-12. PubMed ID: 9469715
[TBL] [Abstract][Full Text] [Related]
9. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Taylor-Robinson SD; Turjanski N; Bhattacharya S; Seery JP; Sargentoni J; Brooks DJ; Bryant DJ; Cox IJ
Metab Brain Dis; 1999 Mar; 14(1):45-55. PubMed ID: 10348313
[TBL] [Abstract][Full Text] [Related]
10. MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Zheng XN; Zhu XC; Ruan LX; Zhang LJ; Yuan M; Shang DS; Liu Y
J Zhejiang Univ Sci; 2004 Feb; 5(2):246-50. PubMed ID: 14674041
[TBL] [Abstract][Full Text] [Related]
11. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
Federico F; Simone IL; Lucivero V; De Mari M; Giannini P; Iliceto G; Mezzapesa DM; Lamberti P
J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):239-42. PubMed ID: 9069478
[TBL] [Abstract][Full Text] [Related]
12. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
13. Metabolic alterations in Parkinson's disease after thalamotomy, as revealed by 1H MR spectroscopy.
Baik HM; Choe BY; Lee HK; Suh TS; Son BC; Lee JM
Korean J Radiol; 2002; 3(3):180-8. PubMed ID: 12271163
[TBL] [Abstract][Full Text] [Related]
14. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Kickler N; Krack P; Fraix V; Lebas JF; Lamalle L; Durif F; Krainik A; Rémy C; Segebarth C; Pollak P
NMR Biomed; 2007 Dec; 20(8):757-62. PubMed ID: 17334978
[TBL] [Abstract][Full Text] [Related]
15. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
16. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
17. [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Aotsuka A; Shinotoh H; Hattori T
Nihon Rinsho; 1997 Jan; 55(1):249-54. PubMed ID: 9014459
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
19. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
Nie K; Zhang Y; Huang B; Wang L; Zhao J; Huang Z; Gan R; Wang L
Parkinsonism Relat Disord; 2013 Mar; 19(3):329-34. PubMed ID: 23238068
[TBL] [Abstract][Full Text] [Related]
20. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
Zhou B; Yuan F; He Z; Tan C
Brain Imaging Behav; 2014 Mar; 8(1):97-101. PubMed ID: 23955491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
